Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:5/27/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 27 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the fourth of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial

----------------

The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 (dirucotide) in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 (dirucotide) versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for an $87 million upfront payment, milestone paymen
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)... DuPont Applied BioSciences has turned to MBI ...g the commercial viability of an important bio-bas...bridging the gap between research and commercializ...d technologies. MBI’s unique “Collabor...resses technological uncertainties, which impede n...
(Date:12/2/2008)...c. 2 GeneGo, Inc., the leading sys...urnham has become a certified GeneGo Center of Exc...-wide access to GeneGo,s MetaCore data analysis su...nstitute is a world-class biomedical research faci...hroughout many departments, including research in ...
(Date:12/2/2008)...c. 2 Intradigm Corporation, a lead...nce (RNAi) therapeutics, today,announced the issu...Methods,and Compositions for Controlling Efficacy...based on the seminal research of Philip Zamore, Ph...Sciences and Professor of Biochemistry,& Mole...
(Date:12/2/2008)...ogy Earns an Innovation Point as a Stand-Alone Pro...ire/ -- The National Geographic Society has used a...to be re-certified as a national leader in energy ...e technology, manufactured by StrionAir of Louisvi...ree points for its LEED-EB 2.0* re-certification a...
Breaking Biology Technology: DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3National Geographic Uses Air Filtration in Bid To Be an Energy, Environmental Leader 2
...our-port Ethernet cards it began offering in Janu...ware for Apple G4 and G4 servers that combines Eth...more bandwidth. , ,The company is the first to pro...erve and Power Mac platforms. In March, it expande...ent Corky Seeber has designs on a market niche tha...
...s implemented IBM s eServer BladeCenter JS20 as t...rt system for proteomics research. IBM announced l...t blade system based on Power Architecture will b...he MCW is the initial customer site to test the Se...Sequest is an application specifically for use in ...
...that China represents phenomenal opportunities for...sconsin companies doing business in China and othe...protect their intellectual property and technology...icant counterfeiting still occurs, despite the eff... to prevent it. Therefore, Wisconsin companies sh...
...l technology subsidiary of Marshall & Ilsley Corpo...itive agreement to acquire the Kirchman Corporati...an Corporation is a provider of automation softwar... The Kirchman Corporation will become a Metavante ...ial Services Group. The transaction, terms of whic...
Other Biology Technology:Small Tree boosts bandwidth for Apple G4 and G5 servers 2Medical College of Wisconsin enhances research with IBM Blade server 2Protecting your intellectual property in overseas markets 2Metavante acquires Florida banking corporation 2
(Date:12/1/2008)...laboration of Stanford University,s Woods Institut...the World Wildlife Fundhas been awarded a two-year...ore Foundation to develop a software program for m...ed by temperate marine ecosystems. , Called Mari...ces and Tradeoffs), the proposed software will giv...
(Date:12/1/2008)...ne site of the journal Biology of Reproduction , ...ime that vitamin D induces immune responses in pla...timicrobial protein cathelicidin. , The study in...o the active form of vitamin D, leading to product... response in the trophoblast cells. , The team, ...
(Date:12/1/2008)...sity] Gray mold is a gardener,s nightmare. The fu...cinerea , is a scourge to more than 200 agricultur... such as tomatoes, strawberries, snap and lima bea...d potatoes. Gray mold envelops its target in a vel... plants, cells, eventually causing the plant to di...
(Date:12/1/2008)...ry" of sea and land animals around a group of Anta...diversity and has more species than the Galapagos....tor how they will respond to future environmental ... Biogeography , the team from British Antarctic Su...combed the land, sea and shores of the South Orkne...
Breaking Biology News(10 mins):Natural Capital Project to develop conservation software 2Brown chemist finds gray mold's killer gene 2Luminex Corporation Third Quarter Earnings Release Scheduled for October 24 2007 1184 1Luminex Corporation Third Quarter Earnings Release Scheduled for October 24 2007 1184 2Luminex Corporation Third Quarter Earnings Release Scheduled for October 24 2007 1184 3Low Lead Exposures Can Hurt Kidneys 3337 1Tooth loss dementia may be linked JADA study suggests 3335 1Microgrid allows simultaneous study of multiple variables 3333 1Microgrid allows simultaneous study of multiple variables 3333 2
...al vaccine can prevent mice from developing a brai... research that will be presented at the American A...n, April 28 ?May 5, 2007. Prion diseases, which in...g disease, are fatal and there is no treatment or ...he body parts of other animals contaminated with p...
...urally occurring molecule in the body appears to c...drenergic receptor agonists used in acute heart fa...iveness over time. , Nitric oxide is a molecule pr...ncluding the contraction or dilation of blood vess...sity Medical Center and Howard Hughes Medical Inst...
...a tree in your tank." Fuel companies aren,t toutin...esearch done in part by Bruce Dale, Michigan State...materials science, making fuels from poplar trees ...t-effective. , Dale is internationally known fo...plant biomass ?the stems, leaves, stalks and trunk...
...umble coral may possess as many genes ?and possibl...hough it is very distant from humans in evolutiona...hat protect people against disease. In fact, it is... , Corals are among the simplest animals in the ...e and complex as our own, says Professor David Mil...
Other Biology News:Vaccine prevents prion disease in mice 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Corals -- More complex than you? 2Corals -- More complex than you? 3
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody.
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)
Includes PROTEAN II xi Basic unit and IPG conversion kit PROTEAN II XL Cell, wide format, Compatible with ReadyStrip IPG Strips 1.0 mm 165-3188 1.5 mm 165-3189 2.0 mm 165-3190
The PROTEAN II xi cell, 16 cm, is used for vertical slab gel electrophoresis of nucleic acids and proteins in agarose gels. The cell is supplied without spacers and combs. The unit includes a central
Biology Products: